Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 425
- Registration Number
- NCT03362814
- Locations
- 🇨🇳
Peking University People's hospital, Beijing, Beijing, China
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03288636
- Locations
- 🇨🇳
The first hospital of Zhejiang province, Hangzhou, Zhejiang, China
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 141
- Registration Number
- NCT03020082
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03020134
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03020004
Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03019991
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 831
- Registration Number
- NCT03017872
- Locations
- 🇦🇷
Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷Hospital Dr Diego Paroissien, Isidro Casanova, Provincia De Buenos Aires, Argentina
🇦🇷CAICI, Rosario, Provincia De Santa Fe, Argentina
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Eiger BioPharmaceuticals
- Registration Number
- NCT02968641
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02948283
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.